You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • FRI0185 Are There Differences in Baseline Characteristics of Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors According To The Presence of Comorbidities?

Article Text

Article menu
Download PDFPDF
Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
FRI0185 Are There Differences in Baseline Characteristics of Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors According To The Presence of Comorbidities?
  1. M.V. Hernández1,
  2. C.A. Sánchez-Piedra2,
  3. J.A. Gόmez-Puerta3,
  4. F. Sánchez-Alonso2,
  5. J. Manero-Ruiz4,
  6. E. Cuende5,
  7. R. Rosello Pardo6,
  8. E. Perez-Pampin7,
  9. C. Rodriguez-Lozano8,
  10. R. Sanmartí1,
  11. J.J. Gόmez-Reino7,
  12. on behalf of BIOBADASER 2.0 Study Group
  1. 1Arthritis Unit. Rheumatology Dpt, Hospital Clínic, Barcelona
  2. 2Research Unit, Spanish Society of Rheumatology, Madrid, Spain
  3. 3Group of Cellular Immunology and Immunogenetics, Universidad de Antioquia, Medellín, Colombia
  4. 4Rheumatology Dpt, Hospital Universitario Miguel Servet, Zaragoza
  5. 5Rheumatology Dpt, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid
  6. 6Rheumatology Dpt, Hospital General San Jorge, Huesca
  7. 7Rheumatology Dpt, Hospital Clínico Universitario, Santiago de Compostela
  8. 8Rheumatology Dpt, Hospital Dr. Negrín, Gran Canaria, Spain

Abstract

Background Rheumatoid arthritis (RA) is often associated with comorbidities that may affect the therapeutic choice or a different management in clinical practice. It is unclear whether patients with comorbidities have a different profile from those without

Objectives To analyze differences in the baseline characteristics of RA patients treated with tumor necrosis factor inhibitors (TNFi) according to the presence or not of concomitant comorbidities

Methods All patients from the BIOBADASER 2.0 register with a diagnosis of RA treated with TNFi from January 2008 to December 2014 were selected and divided into 2 groups according to the presence or not of comorbidities. Comorbidity was defined as ≥1 of the following at initiation of TNFi: ischemic heart disease; malignancy; diabetes; chronic pulmonary obstructive disease; smoking; hypercholesterolemia; hypertension; heart failure; renal failure; osteoporosis; Epstein Barr, hepatitis B or C virus infection; and others. Variables analyzed were: age; gender; disease duration; disease activity at initiation of biological therapy measured by the DAS-28 score; number of previous biological agents (0, 1, ≥2); concomitant glucocorticoids or synthetic DMARD; and biological duration. Differences between groups were analyzed

Results From January 2008 to December 2014, 640 RA treated with TNFi were included in the BIOBADASER 2.0 register. Baseline characteristics are shown in Table 1. Patients with associated comorbidities were significantly older, less frequently female, had received a higher number of previous biologics, and had a higher baseline DAS-28 compared with patients without comorbidities

View this table:
Table 1

Conclusions RA patients treated with TNFi with baseline comorbidities are significantly older, have a higher baseline DAS 28 and had received more previous biologics, suggesting a RA population with higher activity than those without comorbidities. Whether this higher baseline activity favors the development of comorbidities, or whether comorbidities limited therapy in these patients, requires analysis.

Disclosure of Interest None declared

https://doi.org/10.1136/annrheumdis-2016-eular.5799

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.